| Original language | English (US) |
|---|---|
| Pages (from-to) | 416-423 |
| Number of pages | 8 |
| Journal | Annals of Allergy, Asthma and Immunology |
| Volume | 124 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 2020 |
Bibliographical note
Funding Information:Conflicts of interest: These authors disclose the following: Dr Hirano is supported by National Institutes of Health grants U54AI117804 and 1P01DK117824 and has received consulting fees and research support from Adare, Allakos, Celgene, Regeneron, Shire Pharmaceuticals. Dr Chan is a member of the committee for the American Gastroenterological Association and American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force guidelines on the management of eosinophilic esophagitis. Outside of this paper, Dr Chan has received research support from DBV Technologies, has been a member of advisory boards for Pfizer, Pediapharm, Leo Pharma, and Kaleo, is a member of the health care advisory board for Food Allergy Canada, and was an expert panel and coordinating committee member of the National Institute of Allergy and Infectious Disease–sponsored Guidelines for Peanut Allergy Prevention, and is co-lead of the Canadian Society of Allergy and Clinical Immunology oral immunotherapy guidelines. Dr Sharaf receives salary support from National Cancer Institute 1K07CA216326-01A1, NCI 5 R01 CA211723 02, and a Patient-Centered Outcomes Research Institute's Improving Health Systems Award. He is a paid consultant for the nonprofit Institute for Clinical and Economic Review. Dr Stukus received consulting fees from Aimmune Therapeutics, Inc and Before Brands to deliver unbranded educational symposia. Dr Wang served on the advisory board for Ironwood Pharmaceuticals. Dr Greenhawt is supported by grant #5K08HS024599-02 from the Agency for Healthcare Quality and Research, is an expert panel and coordinating committee member of the National Institute of Allergy and Infectious Diseases–sponsored Guidelines for Peanut Allergy Prevention; has served as a consultant for the Canadian Transportation Agency, Thermo Fisher, Intrommune, and Aimmune Therapeutics; is a member of physician/medical advisory boards for Aimmune Therapeutics, DBV Technologies, Sanofi/Genzyme, Genentech, Nutricia, Kaleo Pharmaceutical, Nestle, Aquestive, Allergy Therapeutics, and Monsanto; is a member of the scientific advisory council for the National Peanut Board; has received honorarium for lectures from Thermo Fisher, Aimmune, DBV, Before Brands, multiple state allergy societies, the American College of Allergy, Asthma and Immunology, the European Academy of Allergy and Clinical Immunology; is an associate editor for the Annals of Allergy, Asthma, and Immunology; and is a member of the Joint Taskforce on Allergy Practice Parameters. These relationships are unrelated to the work on this guideline and pose no conflict of interest. The recommendations involving medications undergoing clinical trials were written by members of the guideline committee without conflict of interest. The remaining authors disclose no conflicts.
Funding Information:
This document presents the official recommendations of the American Gastroenterological Association (AGA) and the Joint Task Force on Allergy-Immunology Practice Parameters (JTF) on the management of eosinophilic esophagitis. The guideline was developed jointly by the AGA’s Clinical Practice Guideline Committee and the JTF with approval of both the boards of the American Academy of Allergy, Asthma, and Immunology and the American College of Allergy, Asthma, and Immunology; and approved by both the AGA Governing Board and JTF Governing Boards. Development of this guideline and its accompanying technical review was fully funded by both the AGA Institute and the JTF, with no additional outside funding. The development process followed a standard peer review process as well as a 30-day public commenting period.